Quick links: United States | Major Indices | Indices Future | Real-time Commodities | Webinars | Coronavirus | Economic Calendar
18 Nov 2021
AstraZeneca Covid-19 Preventative Shot Offers 83% Protection for Six Months
The Index Today
On Thursday, AstraZeneca confirmed its new Covid-19 antibody shot aimed at the non-infected population offers 83% protection for around six months. The antibody drug will be provided to people who have are not infected by the virus and show unfavorable response towards the vaccine.
The injection is called Evusheld (AZD7442) and has previously shown protection against the coronavirus symptoms by 77%. The company conducted a separate study in which patents with covid-19 symptoms were giving a higher doze of Evusheld (AZD7442) and saw risks of worsening symptoms reduce by 88%.
According to the long-term follow ups, AstraZenaca confirmed that the effects were lasting, giving the drug maker a strong position against rivals Pfizer. Executive vice president Mene Pangalos said, “These new data add to the growing body of evidence supporting AZD7442 potential to make a significant difference in the prevention and treatment of Covid-19.